Aptose Biosciences Inc (TSE:APS) Director Warren Whitehead Acquires 17,000 Shares

Aptose Biosciences Inc (TSE:APS) (NASDAQ:APTO) Director Warren Whitehead acquired 17,000 shares of Aptose Biosciences stock in a transaction dated Tuesday, June 27th. The shares were bought at an average price of C$1.51 per share, with a total value of C$25,670.00.

Warren Whitehead also recently made the following trade(s):

  • On Wednesday, June 28th, Warren Whitehead purchased 10,000 shares of Aptose Biosciences stock. The stock was acquired at an average price of C$1.60 per share, with a total value of C$16,000.00.
  • On Thursday, June 29th, Warren Whitehead purchased 10,000 shares of Aptose Biosciences stock. The stock was acquired at an average price of C$1.64 per share, with a total value of C$16,400.00.

Aptose Biosciences Inc (TSE:APS) opened at 1.77 on Friday. The firm has a 50-day moving average of $1.72 and a 200 day moving average of $1.50. The firm’s market capitalization is $38.50 million. Aptose Biosciences Inc has a 52 week low of $1.05 and a 52 week high of $4.02.

WARNING: “Aptose Biosciences Inc (TSE:APS) Director Warren Whitehead Acquires 17,000 Shares” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/07/29/aptose-biosciences-inc-tseaps-director-warren-whitehead-buys-17000-shares-updated-updated-updated.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply